2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
21
Carcinoma, Transitional Cell
17
Anus Neoplasms
17
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
11
Appendiceal Neoplasms
11
Stomach Neoplasms
10
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Urologic Neoplasms
4
Sarcoma
4
Carcinoma
4
Anal Canal Carcinoma
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Recurrence
3
Pseudomyxoma Peritonei
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Interventions
Radiotherapy
3
Cisplatin
3
Fluorouracil
2
tislelizumab
1
pembrolizumab
1
motexafin gadolinium
1
Tamoxifen
1
Talaporfin
1
TP protocol
1
Spinal Puncture
1
Rhenium
1
Radiosurgery
1
Poly I-C
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Lomustine
1
Irinotecan
1
Gemcitabine
1
Gadolinium
1
Folfox protocol
1
Ethiodized Oil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cetuximab
1
Carboplatin
1
Blood Specimen Collection
1
Bevacizumab
1
Anesthesia, General
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Recurrence, Local
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts